Irinotecan
- Generic Name
- Irinotecan
- Brand Names
- Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
- Drug Type
- Small Molecule
- Chemical Formula
- C33H38N4O6
- CAS Number
- 97682-44-5
- Unique Ingredient Identifier
- 7673326042
- Background
Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothe...
- Indication
For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluo...
- Associated Conditions
- Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
- Associated Therapies
- -
An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 32
- Registration Number
- NCT06532344
- Locations
- 🇯🇵
National Cancer Center Hospital, Chuo Ku, Japan
🇯🇵Kanagawa Cancer Center, Yokohama-shi, Kanagawa, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06528496
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-07-22
- Target Recruit Count
- 138
- Registration Number
- NCT06512428
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Heilongjiang, Harbin, China
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-12-10
- Target Recruit Count
- 54
- Registration Number
- NCT06509906
- Locations
- 🇺🇸
Sarah Cannon Research Institute at Health One, Denver, Colorado, United States
🇦🇺St George Private Hospital, Kogarah, Australia
🇦🇺Peter MacCallum Cancer Centre - Use the one with Account 2 VCCC, Parkville, Australia
Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 500
- Registration Number
- NCT06509126
- Locations
- 🇮🇹
Istituto Nazionale Tumori di Napoli - IRCCS - Fondazione G. Pascale, Napoli, Italy
Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Rui-hua Xu, MD, PhD
- Target Recruit Count
- 360
- Registration Number
- NCT06501664
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
- Conditions
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Luye Pharma Group Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06496048
- Locations
- 🇨🇳
Jilin Provincial Tumor Hospital, Jilin, China
The Sagittarius Trial
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2024-11-11
- Target Recruit Count
- 700
- Registration Number
- NCT06490536
- Locations
- 🇮🇹
Istituto Clinico Humanitas, Rozzano, Milano, Italy
🇮🇹Istituto di Candiolo, Candiolo, Torino, Italy
🇮🇹Azienda Sanitaria Locale di Biella, Biella, Italy
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
- Conditions
- Interventions
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 686
- Registration Number
- NCT06459180
- Locations
- 🇦🇷
Sanatorio Allende - Cerro-Oncology ( Site 0106), Córdoba, Cordoba, Argentina
🇧🇷Centro de Hematologia e Oncologia ( Site 0203), Joinville, Santa Catarina, Brazil
🇧🇷Americas Centro de Oncologia Integrado ( Site 0202), Rio de Janeiro, Brazil
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Conditions
- Interventions
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 62
- Registration Number
- NCT06450041
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸UCSF Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.